InVivoMAb anti-human Fy3

Catalog #BE0407
Clone:
MIMA-29
Reactivities:
Human

$164.00 - $4,280.00

Choose an Option...
  • 100 mg - $4,280.00
  • 50 mg - $3,024.00
  • 25 mg - $2,009.00
  • 5 mg - $600.00
  • 1 mg - $164.00
  • Custom Amount (Quotes Only)
In stock
Only %1 left

Product Details

The MIMA-29 monoclonal antibody reacts with the Fy3 antigen on Duffy glycoprotein, a seven-pass transmembrane protein also known as Duffy antigen/chemokine receptor (DARC), Fy glycoprotein (FY), and cluster of differentiation 234 (CD234). In humans, Duffy antigen is encoded by the atypical chemokine receptor 1 (Duffy blood group) gene (ACKR1). The antigenic determinants of the Duffy protein include Fya, Fyb, Fy3, Fy4, Fy5, and Fy6, and the polymorphisms observed in the ACKR1 gene form the basis of the Duffy blood group system. The antigens of the Duffy blood group system are mainly expressed on the surface of RBCs. Besides RBCs, these antigens are also expressed in endothelial cells, pulmonary alveolar epithelial cells, renal collecting tubules, and Purkinje cells of the brain. Antibodies against Duffy antigens are involved in transfusion reactions and hemolytic disease of the fetus and newborn (HDFN). Duffy protein also acts as a receptor for the human malaria parasite Plasmodium vivax and the monkey malaria parasite P. knowlesi. Duffy protein is involved in the regulation of leucocyte recruitment to inflammatory sites, and it also facilitates the trans-endothelial movement of chemokines. Among various Duffy antigens, Fy3 is the most prevalent and a clinically significant antigen. Fy3 antigen is often detected using flow cytometry with the MIMA-29 antibody, and synthetic peptide-based experiments have shown that the MIMA-29 antibody recognizes either a linear epitope of amino acid 281-285 (ALDLL) in the fourth extracellular domain (ECD4, loop 3) or a conformational epitope that includes amino acid residues of ECD4 and of other extracellular domains of Duffy glycoprotein. The MIMA-29 monoclonal antibody has been used in vivo for the targeting of RBCs in HOD mice that express an RBC-restricted triple fusion protein HOD antigen (HOD Ag) consisting of hen egg lysozyme (HEL), ovalbumin (OVA), and human blood group molecule Duffy. In another in vivo study involving antibody-mediated immune suppression (AMIS) experimental models with HOD and other strains of mice, the MIMA 29 antibody was shown to induce an AMIS effect at the level of IgM and all isotypes of IgG.

Specifications

Isotype Mouse IgG2a, κ
Recommended Isotype Control(s) InVivoMAb mouse IgG2a isotype control, unknown specificity
Recommended Dilution Buffer InVivoPure pH 7.0 Dilution Buffer
Conjugation This product is unconjugated. Conjugation is available via our Antibody Conjugation Services.
Immunogen Fyb transfected 293T cells
Reported Applications in vivo targeting of HOD Ag+ RBCs
in vitro targeting of HOD Ag+ RBCs
Indirect Antiglobulin Test (IAT)
Immunohistochemistry (paraffin)
Functional assays
Flow cytometry
ELISA
Formulation PBS, pH 7.0
Contains no stabilizers or preservatives
Endotoxin <2EU/mg (<0.002EU/μg)
Determined by LAL gel clotting assay
Purity >95%
Determined by SDS-PAGE
Sterility 0.2 µm filtration
Production Purified from cell culture supernatant in an animal-free facility
Purification Protein A
Molecular Weight 150 kDa
Storage The antibody solution should be stored at the stock concentration at 4°C. Do not freeze.